Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

  • Maiques-Diaz, A
  • Chou, F S
  • Wunderlich, M
  • Gómez-López, G
  • Jacinto, F V
  • Rodriguez Perales, Sandra
  • Larrayoz, M J
  • Calasanz, M J
  • Mulloy, J C
  • Cigudosa, J C
  • Alvarez, S
The AML1-ETO fusion protein, which is present in 10-15% of cases of acute myeloid leukemia, is known to repress myeloid differentiation genes through DNA binding and recruitment of chromatin-modifying proteins and transcription factors in target genes. ChIP-chip analysis of human hematopoietic stem/progenitor cells transduced with the AML1-ETO fusion gene enabled us to identify 1168 AML1-ETO target genes, 103 of which were co-occupied by histone deacetylase 1 (HDAC1) and had lost the hyperacetylation mark at histone H4, and 264 showed a K9 trimethylation at histone H3. Enrichment of genes involved in hematopoietic differentiation and in specific signaling pathways was observed in the presence of these epigenetic modifications associated with an 'inactive' chromatin status. Furthermore, AML1-ETO target genes had a significant correlation between the chromatin marks studied and transcriptional silencing. Interestingly, AML1 binding sites were absent on a large number of selected AML1-ETO promoters and an Sp1 binding site was found in over 50% of them. Reversible silencing induced by the fusion protein in the presence of AML1 and/or Sp1 transcription factor binding site was confirmed. Therefore, this study provides a global analysis of AML1-ETO functional chromatin modifications and identifies the important role of Sp1 in the DNA binding pattern of AML1-ETO, suggesting a role for Sp1-targeted therapy in this leukemia subtype.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma

  • Martín-Pérez, D.
  • Vargiu, P.
  • Montes-Moreno, Noemí
  • Andrés-León, Eduardo
  • Rodríguez-Pinilla, S. M.
  • Lisio, Lorena di
  • Martínez Martínez, Noelia
  • Rodríguez, R.
  • Mollejo, M.
  • Castellvi, J.
  • Pisano, David G.
  • Sánchez-Beato, M.
  • Piris, M. A.
We have studied the miRNA expression profile in 36 DLBCL samples using miRNA microarrays. Prevalence of EBV in this series (33 EBV-negative and 3 EBV-positive) was close to normal prevalence in DLBCL.1 Twenty-two out of thirty-two analysed viral miRNAs were significantly upregulated in EBV-positive samples (>two-fold change; t-test corrected P-value<0.05, Figure 1c, Supplementary table 2 and Supplementary table 3)., We would like to acknowledge all members of CNIOs Lymphoma Group for their thoughtful discussion. This study was funded with the following grants: from Ministerio de Educacio´n y Ciencia, Spain SAF2007-65957-C02-02, SAF2008-03871; from the Fondo de Investigaciones Sanitarias, RTICC RD06/0020/0107 and PI10/ 00621; from Fundacio´n Cientı´fica de la Asociacio´n Espan˜ola Contra el Ca´ncer (AECC). LDL is supported by a fellowship from Ministerio de Sanidad y Consumo (FI08/00038); NM is supported by a contract from Ministerio de Sanidad y Consumo (CP06/00002)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder

  • Amann, Benedikt L.|||0000-0002-4407-1519
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Madre Rull, Mercè|||0000-0002-4660-3216
  • Radua, Joaquim|||0000-0003-1240-5438
  • Monte, G.
  • Alonso-Lana, Silvia|||0000-0002-3063-6929
  • Landin-Romero, Ramon|||0000-0003-0485-8090
  • Moreno Alcázar, Ana|||0000-0002-3392-5590
  • Bonnin, Caterina del Mar|||0000-0002-1197-1596
  • Sarró, Salvador|||0000-0003-1835-2189
  • Ortiz-Gil, Jordi|||0000-0001-7910-8062
  • Gomar, J. J.
  • Moro, N.
  • Fernandez-Corcuera, P.
  • Goikolea Alberdi, Jose Manuel|||0000-0003-0676-0791
  • Blanch, J.
  • Salvador, R.
  • Vieta, Eduard|||0000-0002-0548-0053
  • McKenna, P. J.
  • Pomarol-Clotet, E.
Brain structural changes in schizoaffective disorder, and how far they resemble those seen in schizophrenia and bipolar disorder, have only been studied to a limited extent. Forty-five patients meeting - and criteria for schizoaffective disorder, groups of patients with 45 matched schizophrenia and bipolar disorder, and 45 matched healthy controls were examined using voxel-based morphometry (). Analyses comparing each patient group with the healthy control subjects found that the patients with schizoaffective disorder and the patients with schizophrenia showed widespread and overlapping areas of significant volume reduction, but the patients with bipolar disorder did not. A subsequent analysis compared the combined group of patients with the controls followed by extraction of clusters. In regions where the patients differed significantly from the controls, no significant differences in mean volume between patients with schizoaffective disorder and patients with schizophrenia in any of five regions of volume reduction were found, but mean volumes in the patients with bipolar disorder were significantly smaller in three of five. The findings provide evidence that, in terms of structural gray matter brain abnormality, schizoaffective disorder resembles schizophrenia more than bipolar disorder.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metabolites related to purine catabolism and risk of type 2 diabetes incidence, modifying effects of the TCF7L2-rs7903146 polymorphism

  • Papandreou, Christopher|||0000-0002-6803-507X
  • Li, Jun
  • Liang, Liming|||0000-0001-8261-3174
  • Bulló, Mònica|||0000-0002-0218-7046
  • Zheng, Yan
  • Ruiz-Canela, Miguel|||0000-0002-7684-2787
  • Yu, Edward
  • Guasch-Ferré, Marta
  • Razquín, Cristina|||0000-0003-3480-2645
  • Clish, Clary|||0000-0001-8259-9245
  • Corella, Dolores|||0000-0002-2366-4104
  • Estruch, Ramón|||0000-0003-1260-4445
  • Ros, Emilio|||0000-0002-2573-1294
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Arós, Fernando
  • Serra-Majem, Luís|||0000-0002-9658-9061
  • Rosique, Nuria
  • Martínez-González, Miguel A.
  • Hu, Frank B..
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. We prospectively examined associations between plasma levels of purine metabolites with T2D risk and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further investigated.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus, Relationship with Cardiovascular Risk Factors. A Case-Control Study

  • Llauradó, Gemma|||0000-0002-3237-6366
  • González Clemente, José Miguel|||0000-0002-7409-8720
  • Maymó-Masip, Elsa
  • Subías, David
  • Vendrell, Joan|||0000-0002-6994-6115
  • Chacón, Matilde R.
To test the usefulness of serum concentrations of tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and soluble scavenger receptor CD163 (sCD163) as markers of subtle inflammation in patients with type 1 diabetes mellitus (T1DM) without clinical cardiovascular (CV) disease and to evaluate their relationship with arterial stiffness (AS). Sixty-eight patients with T1DM and 68 age and sex-matched, healthy subjects were evaluated. Anthropometrical variables and CV risk factors were recorded. Serum concentrations of sTWEAK and sCD163 were measured. AS was assessed by aortic pulse wave velocity (aPWV). All statistical analyses were stratified by gender. T1DM patients showed lower serum concentrations of sTWEAK (Men: 1636.5 (1146.3-3754.8) pg/mL vs. 765.9 (650.4-1097.1) pg/mL; p<0.001. Women: 1401.0 (788.0-2422.2) pg/mL vs. 830.1 (562.6-1175.9) pg/mL; p = 0.011) compared with their respective controls. Additionally, T1DM men had higher serum concentrations of sCD163 (285.0 (247.7-357.1) ng/mL vs. 224.8 (193.3-296.5) ng/mL; p = 0.012) compared with their respective controls. sTWEAK correlated negatively with aPWV in men (r = -0.443; p<0.001). However, this association disappeared after adjusting for potential confounders. In men, the best multiple linear regression model showed that the independent predictors of sTWEAK were T1DM and WHR (R 2 = 0.640; p<0.001). In women, T1DM and SBP were the independent predictors for sTWEAK (R 2 = 0.231; p = 0.001). sTWEAK is decreased in T1DM patients compared with age and sex-matched healthy subjects after adjusting for classic CV risk factors, although sTWEAK levels may be partially influenced by some of them. Additionally, T1DM men have higher serum concentrations of sCD163. These results point out an association between the inflammatory system and CV risk in T1DM.